NYSE - Delayed Quote • USD
Teva Pharmaceutical Industries Limited (TEVA)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 6:54 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 7 | 7 | 12 | 13 |
Avg. Estimate | 0.51 | 0.58 | 2.41 | 2.64 |
Low Estimate | 0.47 | 0.54 | 2.3 | 2.54 |
High Estimate | 0.54 | 0.61 | 2.5 | 2.8 |
Year Ago EPS | 0.4 | 0.56 | 2.56 | 2.41 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 7 | 7 | 12 | 12 |
Avg. Estimate | 3.73B | 4B | 15.87B | 16.34B |
Low Estimate | 3.63B | 3.95B | 15.57B | 15.84B |
High Estimate | 3.82B | 4.08B | 16.04B | 16.68B |
Year Ago Sales | 3.63B | -- | 15.85B | 15.87B |
Sales Growth (year/est) | 2.80% | -- | 0.10% | 3.00% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | 0.56 | 0.52 | 0.61 | 0.77 |
EPS Actual | 0.4 | 0.56 | 0.6 | 1 |
Difference | -0.16 | 0.04 | -0.01 | 0.23 |
Surprise % | -28.60% | 7.70% | -1.60% | 29.90% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | 0.51 | 0.58 | 2.41 | 2.64 |
7 Days Ago | 0.52 | 0.58 | 2.41 | 2.64 |
30 Days Ago | 0.52 | 0.58 | 2.4 | 2.63 |
60 Days Ago | 0.52 | 0.58 | 2.4 | 2.63 |
90 Days Ago | 0.5 | 0.58 | 2.42 | 2.59 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | 1 | 1 |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | 1 | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | TEVA | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 27.50% | -- | -- | 6.50% |
Next Qtr. | 3.60% | -- | -- | 12.00% |
Current Year | -5.90% | -- | -- | 5.30% |
Next Year | 9.50% | -- | -- | 13.10% |
Next 5 Years (per annum) | 1.60% | -- | -- | 11.09% |
Past 5 Years (per annum) | 1.90% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Upgrade | JP Morgan: Underweight to Neutral | 3/8/2024 |
Upgrade | Piper Sandler: Neutral to Overweight | 2/12/2024 |
Maintains | Goldman Sachs: Neutral to Neutral | 2/5/2024 |
Maintains | Barclays: Overweight to Overweight | 2/5/2024 |
Maintains | Barclays: Overweight to Overweight | 1/29/2024 |
Upgrade | Jefferies: Hold to Buy | 1/23/2024 |
Related Tickers
VTRS Viatris Inc.
11.57
+0.87%
ALVO Alvotech
14.15
+3.66%
ELAN Elanco Animal Health Incorporated
13.26
+1.69%
BHC Bausch Health Companies Inc.
8.71
+1.04%
PRGO Perrigo Company plc
31.94
+2.14%
TLRY Tilray Brands, Inc.
1.7800
+1.71%
DVAX Dynavax Technologies Corporation
11.21
+0.36%
ACB Aurora Cannabis Inc.
6.70
-0.15%
ESPR Esperion Therapeutics, Inc.
1.9000
-4.52%
TAK Takeda Pharmaceutical Company Limited
13.03
-0.31%